News

Bioasis is focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier. As part of the deal, MedImmune will assess the therapeutic effect of its

Mogamulizumab, which is branded as ‘POTELIGEO Injection’, is a novel, humanized monoclonal antibody directed against CC chemokine receptor 4 (CCR4), which is over-expressed on various malignant T cells,

Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of degenerative diseases. Magnum’s facilities include a clinic

The move follows an approval from the European Commission in November 2013. Currently, Abilify Maintena is available in several European countries and is progressing through the various Healthcare

Under the deal, BMS will use Five Prime’s platform to move forward its existing immuno-oncology programs by identifying the most viable drug targets for continued research and development.

If successful, both companies will collaborate on developing the imaging flow technology platform for future commercialization in hematology. Currently, Sysmex is conducting a clinical study assessing EMD Millipore’s

Trellis’ discovery platform, called CellSpot, uses computerized microscopy to drastically miniaturize a multiplexed antigen binding assay capable of characterizing millions of individual antibody producing B cells. Hence, CellSpot

The strategic collaboration is designed to support the commercial development of Generx and Excellagen by Taxus Cardium, and also to provide new opportunities to explore the commercialization of

Drs Kratz and Warnecke and their scientific team will expand the Corporation’s novel albumin-binding anti-cancer drug pipeline. Dr Kratz, one of the most highly regarded conjugation chemists in